Free Trial

Purple Biotech (PPBT) Competitors

Purple Biotech logo
$2.33 -0.09 (-3.72%)
Closing price 06/20/2025 03:57 PM Eastern
Extended Trading
$2.40 +0.06 (+2.79%)
As of 06/20/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PPBT vs. LIPO, NEUP, ALLR, ATHA, TXMD, NERV, AYTU, EQ, BCDA, and PHIO

Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Lipella Pharmaceuticals (LIPO), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Allarity Therapeutics (ALLR), Athira Pharma (ATHA), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Aytu BioPharma (AYTU), Equillium (EQ), BioCardia (BCDA), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry.

Purple Biotech vs. Its Competitors

Lipella Pharmaceuticals (NASDAQ:LIPO) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.

Purple Biotech received 16 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 94.44% of users gave Purple Biotech an outperform vote.

CompanyUnderperformOutperform
Lipella PharmaceuticalsOutperform Votes
1
100.00%
Underperform Votes
No Votes
Purple BiotechOutperform Votes
17
94.44%
Underperform Votes
1
5.56%

Purple Biotech has a consensus target price of $33.00, suggesting a potential upside of 1,316.31%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Purple Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Purple Biotech has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Purple Biotech's return on equity of -17.84% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Purple Biotech N/A -17.84%-15.44%

In the previous week, Lipella Pharmaceuticals had 2 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Lipella Pharmaceuticals and 1 mentions for Purple Biotech. Lipella Pharmaceuticals' average media sentiment score of 0.50 beat Purple Biotech's score of 0.00 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lipella Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Purple Biotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lipella Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Lipella Pharmaceuticals has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$540K13.66-$5.02M-$4.08-0.40
Purple BiotechN/AN/A-$7.24M-$2.62-0.89

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Purple Biotech beats Lipella Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PPBT vs. The Competition

MetricPurple BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.22M$2.83B$5.20B$8.59B
Dividend YieldN/A2.47%5.36%4.20%
P/E Ratio-0.8921.3325.7519.16
Price / SalesN/A231.34395.33100.88
Price / CashN/A42.6935.5255.99
Price / Book0.097.417.985.79
Net Income-$7.24M-$55.11M$3.15B$248.88M
7 Day Performance-4.31%-2.18%1.27%2.13%
1 Month Performance-1.69%7.19%4.91%4.30%
1 Year PerformanceN/A-1.11%41.84%15.71%

Purple Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PPBT
Purple Biotech
1.9406 of 5 stars
$2.33
-3.7%
$33.00
+1,316.3%
N/A$3.22MN/A-0.8920
LIPO
Lipella Pharmaceuticals
1.4729 of 5 stars
$2.87
+8.7%
N/A-68.0%$12.82M$536.36K-0.684News Coverage
Gap Down
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A$6.70
-1.8%
$21.00
+213.4%
N/A$12.60M$15.66M0.00N/APositive News
ALLR
Allarity Therapeutics
N/A$0.83
+3.8%
N/A-93.2%$12.58MN/A0.0010
ATHA
Athira Pharma
2.3155 of 5 stars
$0.32
+5.4%
$13.83
+4,217.5%
-86.8%$12.51MN/A-0.1140Positive News
Gap Up
TXMD
TherapeuticsMD
0.7971 of 5 stars
$1.08
-7.7%
N/A-41.1%$12.50M$1.84M0.00420
NERV
Minerva Neurosciences
3.4575 of 5 stars
$1.78
-1.1%
$5.00
+180.9%
-47.8%$12.45MN/A-4.059News Coverage
AYTU
Aytu BioPharma
1.2806 of 5 stars
$1.98
+1.5%
N/A-28.1%$12.22M$81.66M-1.37160
EQ
Equillium
2.4552 of 5 stars
$0.34
-2.0%
$3.00
+782.1%
-50.8%$12.15M$30.41M-2.4340
BCDA
BioCardia
3.522 of 5 stars
$2.30
+5.5%
$25.00
+987.0%
-38.5%$11.91M$3K-0.5540Gap Up
PHIO
Phio Pharmaceuticals
3.0922 of 5 stars
$2.48
+9.3%
$14.00
+464.5%
-64.6%$11.90MN/A-0.2310

Related Companies and Tools


This page (NASDAQ:PPBT) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners